Liu Mingtao, Gan Hui, Liang Zhiman, Liu Li, Liu Qiwen, Mai Yiyin, Chen Huihuang, Lei Baoying, Yu Shangwei, Chen Huihui, Zheng Peiyan, Sun Baoqing
National Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, China.
Guangzhou Medical University, Guangzhou, China.
Front Microbiol. 2023 Mar 16;14:1122868. doi: 10.3389/fmicb.2023.1122868. eCollection 2023.
COVID-19 pandemic is a global public health emergency. Despite extensive research, there are still few effective treatment options available today. Neutralizing-antibody-based treatments offer a broad range of applications, including the prevention and treatment of acute infectious diseases. Hundreds of SARS-CoV-2 neutralizing antibody studies are currently underway around the world, with some already in clinical applications. The development of SARS-CoV-2 neutralizing antibody opens up a new therapeutic option for COVID-19. We intend to review our current knowledge about antibodies targeting various regions (i.e., RBD regions, non-RBD regions, host cell targets, and cross-neutralizing antibodies), as well as the current scientific evidence for neutralizing-antibody-based treatments based on convalescent plasma therapy, intravenous immunoglobulin, monoclonal antibodies, and recombinant drugs. The functional evaluation of antibodies (i.e., or assays) is also discussed. Finally, some current issues in the field of neutralizing-antibody-based therapies are highlighted.
新冠疫情是一场全球突发公共卫生事件。尽管进行了广泛研究,但目前仍几乎没有有效的治疗方案。基于中和抗体的治疗方法具有广泛应用,包括预防和治疗急性传染病。目前全球有数百项针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)中和抗体的研究正在进行,其中一些已应用于临床。SARS-CoV-2中和抗体的研发为新冠病毒病(COVID-19)开辟了一种新的治疗选择。我们打算综述我们目前关于靶向各个区域(即受体结合域(RBD)区域、非RBD区域、宿主细胞靶点和交叉中和抗体)的抗体的知识,以及基于康复期血浆疗法、静脉注射免疫球蛋白、单克隆抗体和重组药物的基于中和抗体治疗的当前科学证据。还讨论了抗体的功能评估(即 或 检测)。最后,强调了基于中和抗体疗法领域当前的一些问题。